Question? Call us
212-363-7500Expired
Lead Plaintiff Deadline
Dec 15, 2025
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
The filed complaint alleges that MoonLake Immunotherapeutics made materially false and/or misleading statements and/or failed to disclose that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
In order to be eligible to join the MLTX class action lawsuit, you must have incurred a loss on shares of MoonLake purchased during the class period listed above.
If you suffered a loss in MoonLake during the relevant time frame or pursuant to the relevant offering(s), you have until December 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP